Journal article

Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry

Victor Khou, James J Anderson, Geoff Strange, Carolyn Corrigan, Nicholas Collins, David S Celermajer, Nathan Dwyer, John Feenstra, Mark Horrigan, Dominic Keating, Eugene Kotlyar, Melanie Lavender, Tanya J McWilliams, Peter Steele, Robert Weintraub, Helen Whitford, Ken Whyte, Trevor J Williams, Jeremy P Wrobel, Anne Keogh Show all

Respirology | WILEY | Published : 2020


Funding Acknowledgements

Funding for the registry was provided by Actelion, Allied Healthcare, Bayer, GlaxoSmithKline, Novartis and Pfizer via unrestricted grants to the PHSANZ. J.J.A. has received research support from GlaxoSmithKline and travel grants from Actelion and Bayer. G.S. reports grants from Actelion, Bayer, Pfizer Pharmaceuticals and GlaxoSmithKline, and personal fees from Actelion, Arena Pharmaceuticals, Bayer and GlaxoSmithKline outside the submitted work. N.C. has received research support and travel grants from Actelion. N.D. has received advisory payments from Actelion, GlaxoSmithKline and Bayer. M.H. has received research support from Actelion. D.K. has received speaking fees from GlaxoSmithKline, Actelion and Novartis. E.K. has received honoraria for speaking for Actelion, Bayer, Novartis, Servier and GlaxoSmithKline; has served on the advisory board for GlaxoSmithKline, Actelion and Bayer; and received research grants from GlaxoSmithKline and Actelion. M.L. has acted as a paid consultant to GlaxoSmithKline, Actelion and Bayer, and has received educational grants from GlaxoSmithKline, Actelion and Bayer. H.W. has received honoraria, speaker fees, travel grants and advisory board fees from Actelion, GlaxoSmithKline and Bayer. T.J.W. has served on scientific advisory boards of Actelion, GlaxoSmithKline and Bayer, and has received research and teaching support from Actelion. J.P.W. has received speaking fees, advisory board and travel grants from Actelion, Boehringer Ingelheim and Roche, and speaking fees and travel grants from GlaxoSmithKline. A.K. has served on advisory boards of Actelion, GlaxoSmithKline and Bayer, and participated in clinical trials sponsored by Actelion, Bayer, Pfizer, Gilead, Arena, Respira, Acceleron, Pfizer and Bellerophon. E.M.L. has received speaking and consultancy fees from Actelion and Menarini Pharmaceuticals, and has received research support from Actelion and GlaxoSmithKline.